International Journal of Inflammation

Review Article

Contradictory Immune Response in Post Liver Transplantation Hepatitis B and C

Table 2

Post-OLT HBV vaccine administration trials.


	Methods	Definition of success	Success rate (%)	Reference number	Reported year

Liver cirrhosis	10–20 μg monthly with experimentally minimized immunosuppressant	HBsAb >100 IU/L without HBIG	64	[118]	2009
	20 μg monthly	HBsAb >100 IU/L 6 months without HBIG	40	[117]	2013
	20 μg monthly	HBsAb >100 IU/L 3 months without HBIG	0	[112]	2011
	40 μg 0, 1, 2, 6, 7, and 8 months	HBsAb >100 IU/L without HBIG	0	[114]	2009
	40 μg 0, 1, and 6 months	HBsAb >10 IU/L without HBIG	82	[113]	2000
	20–40 μg 0, 1, and 6 months	HBsAb >10 IU/L 16 months without HBIG	0	[115]	2010
	20 μg with MPL adjuvant 12 monthly	HBsAb >100 IU/L 18 months without HBIG	44.8	[129]	2010
	Experimental adjuvant vaccine 0, 1, 2, 6, and 12 months	HBsAb >500 IU/L 18 months without HBIG	25	[119]	2005

Acute liver failure	20 μg monthly	HBsAb >100 IU/L 6 months without HBIG	100	[117]	2013
	Experimental adjuvant vaccine 0, 1, 2, 6, and 12 months	HBsAb >500 IU/L 18 months without HBIG	100	[119]	2005
	10–20 μg monthly	HBsAb >100 IU/L without HBIG	66	[118]	2009

Non-HBV-related patients with HBcAb positive donors	20 μg monthly	HBsAb >100 IU/L 3 months without HBIG	83	[112]	2011
	Infant 20–40 μg according to body weight 2–4 times/year	HBsAb >100 IU/L without HBIG	75	[121]	2007
	20 μg 0, 1, and 6 months	HBsAb >100 IU/L 6 months without HBIG	50	[120]	2007

OLT: orthotopic liver transplantation, HBV: hepatitis B virus, HBIG: hepatitis B immunoglobulin, IU: international unit, and HBsAb: anti-hepatitis B s antibody.